Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1999-03-01
2000-08-01
Celsa, Bennett
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 9, 514 11, 4241851, A61K 3805
Patent
active
060967137
ABSTRACT:
Disclosed are methods of inhibiting neovascularization in a subject by administering to the subject a pharmaceutical preparation of R'-Glu-Trp-R".
REFERENCES:
patent: 4191753 (1980-03-01), Ryan
patent: 5100873 (1992-03-01), de Castiglione et al.
patent: 5538951 (1996-07-01), Morozov et al.
patent: 5728680 (1998-03-01), Morozov et al.
patent: 5767087 (1998-06-01), Morozov et al.
patent: 5770576 (1998-06-01), Morozov et al.
patent: 5902790 (1999-05-01), Green et al.
Daly, T. J. et al., "High Acitivity Suppression of Myeloid Progenitor Proliferation by Chimeric Mutants of Interleukin 8 and Platelet Factor 4," The Journal of Biological Chemistry, vol. 270, No. 40, Oct. 6, 1995, pp. 23282-23292.
Database WPI, Section Ch, Week 9212, Derwent Publications Ltd., London, GB; Class B04, AN 92-094519, XP002023101 & SU, A, 1 642 398 (Rost Med Inst), Apr. 15, 1991, Abstract Only.
Database WPI, Section Ch, Week 9501, Derwent Publications Ltd., London, GB; Class B05, AN 95-004962, XP002023100 & SU, A, 1 827 255 (Kiev Doctor Training Inst), Jul. 15, 1993. Abstract Only.
Database WPI, Section Ch, Week 9511, Derwent Publications Ltd., London, GB; Class B05, AN 95-080267, XP002023102 & RU, C, 2 014 063 (Sochi Spas Physiotherapy Res Ints), Jun. 15, 1994, Abstract Only.
Folkman, J., "What Is the Evidence That Tumors Are Angiogenesis Dependent?," Journal of the National Cancer Institute, vol. 82, No. 1, Jan. 3, 1990, pp. 4-6.
Frater-Schroder et al., "Tumor necrosis factor type .alpha., a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo," Proc. Natl. Acad. Sci. USA, vol. 84, Aug. 1987, pp. 5277-5281.
Heimark, R.L. et al., "Inhibition of Endothelial Regeneration by Type-Beta Transforming Growth Factor from Platelets," Science, vol. 233, Sep. 5, 1986, pp. 1078-1080.
Kahn, J.O. et al., "Intralesional Recombinant Tumor Necrosis Factor-.alpha. for AIDS-Associated Kaposi's Sarcoma: A Randomized, Double-Blind Trial," Journal of Acquired Immune Deficiency Syndromes, vol. 2, No. 3, (1989) pp. 217-223.
Knighton, D. et al., "Avascular And Vascular Phases Of Tumor Growth In The Chick Embryo," Br. J. Cancer, vol. 35, pp. 347-336.
Maione, T.E., "Direct Clinical Applications of Chemokines," IBM Conference "Chemotactic Cytokines" Oct. 26, 1995.
Maione, T.E. et al., "Development of angiogenesis inhibitors for clinical applications," Trends in Pharmaceutical Sciences, vol. 11, Nov. 1990, pp. 457-460.
Nakamura, S. et al., "Kaposi's Sarcoma Cells: Long-Term Culture with Growth Factor from Retrovirus-Infected CD4+ T Cells," Science, vol. 242, Oct. 21, 1988, pp. 426-430.
Rodionov et al., "The Immunocorrective Therapy of Pyoderma Caused by Staphylococci Multiply Resistant to Antibiotics," Vestn. Dermatol. Venerol, vol. 1, (Medline Abstract No. 90224329) (1990) pp. 42-45.
Sidky, Y.A. et al., "Inhibition of Angiogenesis by Interferons: Effects on Tumor-and Lymphocyte-induced Vascular Responses," Cancer Research, vol. 47, Oct. 1, 1987, pp. 5155-5161.
Wiseman, D.M. et al., "Transforming Growth Factor-Beta (TGF.beta.) Is Chemotactic For Human Monocytes And Induces Their Expression of Angiogenic Activity," Biochemical and Biophysical Research Communications, vol. 157, No. 2, Dec. 15, 1988, pp. 793-800.
Blasecki John W.
Green Lawrence R.
Celsa Bennett
Cytran, Inc.
LandOfFree
Pharmaceutical angiostatic dipeptide compositions and methods of does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical angiostatic dipeptide compositions and methods of, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical angiostatic dipeptide compositions and methods of will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-663926